Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2100049734Phase 4Recruiting
- Sponsor
- Sanmenxia Central Hospital
- Start
- Jun 2021
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Sanmenxia Central Hospital. Primary endpoint: progression-free survival. Started Jun 2021; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2100049734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049734.